Related Experiment Video
Updated: May 6, 2026
10:51
Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device
Published on: August 30, 2016
22.4K
Bioengineered human gut-on-a-chip for advancing non-clinical pharmaco-toxicology
Yong Cheol Shin1, Nam Than1, Soo Jin Park1
1Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Expert Opinion on Drug Metabolism & Toxicology
|June 7, 2024
Summary
Human organ-on-a-chip models, specifically gut-on-a-chip platforms, offer a promising alternative to traditional non-clinical models for predicting drug responses and toxicity.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Microbiome Research
Background:
- Current non-clinical models often fail to accurately predict human drug responses.
- Human organ-on-a-chip models, particularly gut-on-a-chip platforms, are emerging as advanced alternatives.
Purpose of the Study:
- To summarize recent advances in human gut-on-a-chip models.
- To highlight their role as a bridge between non-clinical and clinical drug assessment.
- To emphasize their potential for investigating host-microbiome-drug interactions.
Main Methods:
- Review of up-to-date human gut-on-a-chip models.
- Analysis of their capacity to simulate human intestinal microenvironment.
- Focus on host, microbiome, and pharmaceutical compound interactions.
Main Results:
- Gut-on-a-chip models recreate complex human intestinal conditions (e.g., flow, oxygen gradients, microbiome interactions).
- These platforms offer a reliable framework for studying drug metabolism and toxicity.
- They enable investigation of the gut microbiome's impact on drug efficacy.
Conclusions:
- Gut-on-a-chip technology provides a predictive, human-relevant, non-clinical model.
- It addresses knowledge gaps in drug toxicology and metabolism by simulating intricate biological processes.
- These platforms are crucial for advancing pharmaceutical research and development.
